SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2020

Revenue by payor class as a percentage of total net service revenue is as follows:


	For the Three-Month Periods Ended June 30,						For the Six-Month Periods Ended June 30,
	2020		2019		2020		2019
Home Health:
Medicare	40	%	44	%	41	%	45	%
Non-Medicare - Episodic-based	6	%	9	%	6	%	9	%
Non-Medicare - Non-episodic based	14	%	12	%	14	%	12	%
Hospice (1):
Medicare	34	%	30	%	33	%	29	%
Non-Medicare	2	%	1	%	2	%	1	%
Personal Care	4	%	4	%	4	%	4	%
	100	%	100	%	100	%	100	%
(1) Acquired Compassionate Care Hospice on February 1, 2019, RoseRock Healthcare on April 1, 2019, Asana Hospice on January 1, 2020 and AseraCare on June 1, 2020.

Schedule of Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ (amounts in millions):


	Fair Value at Reporting Date Using
Financial Instrument	Carrying Value as of June 30, 2020		Quoted Prices in Active Markets for Identical Items (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Long-term obligations	$	403.6	$	—	$	404.1	$	—

Schedule of Weighted-Average Shares Outstanding

The following table sets forth, for the periods indicated, shares used in our computation of the weighted-average shares outstanding, which are used to calculate our basic and diluted net income attributable to Amedisys, Inc. common stockholders (amounts in thousands):


	For the Three- Month Periods Ended June 30,			For the Six- Month Periods Ended June 30,
	2020	2019	2020	2019
Weighted average number of shares outstanding - basic	32,412	32,075	32,371	32,038
Effect of dilutive securities:
Stock options	570	537	582	548
Non-vested stock and stock units	303	321	306	327
Weighted average number of shares outstanding - diluted	33,285	32,933	33,259	32,913
Anti-dilutive securities	14	159	21	143